---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041578"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:56:31.977708+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology to merge with Apexigen in stock deal; Pyxis shareholders to own 90% of combined company

## Summary
- Exchange ratio: 0.1725 Pyxis shares per Apexigen share; combined ownership ~90% Pyxis, ~10% Apexigen.
- Estimated purchase price ~$15.1M based on Pyxis closing price of $3.19 on June 5, 2023.
- Pro forma combined net loss for FY2022: $158.9M; for Q1 2023: $25.3M.
- Pro forma combined cash and marketable securities ~$161.4M as of March 31, 2023.
- Apexigen options, RSUs, and warrants assumed and converted with substantially similar terms.

## SEC filing metadata
- accession: 0000950170-23-041578
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/0000950170-23-041578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/pyxs-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041578
- JSON: https://secwatch.observer/filing/0000950170-23-041578.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.